Microbix Biosystems Inc (MBXBF)

[yielddude]

Kinlytic continued ...

Back in May, Microbix partnered with Sequel Pharma to bring back Kinlytic to the market. So far, they have received $4M in payments, will receive another million upon filing the supplemental BLA, can earn $30M with sales milestone payments. ALSO, they will earn double digit royalties on sales, which are estimated at $15 to $25M per year once fully ramped up.
This is based on the catheter clearance market in the U.S. only. Eventually that may expand to Europe, Canada, and other continents/countries. It may also expand to other indications (thrombolytic therapy/embolism). And Microbix will continue to get royalties.